Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
The New Criterion’s Tim Boreham highlights Arovella Therapeutics in a struggling cell therapies sector worldwide
Aug 29 2024
Sleep treatment leader ResMed has faced a number of headwinds but has surprised analysts with a strong improvement in gross margins
Aug 07 2024
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| ARX | AROA BIOSURGERY LIMITED | $0.66 | $0.87 | $0.44 | 118.8 |
$0.975 |
| AVH | AVITA MEDICAL INC | $3.93 | $5.62 | $2.34 |
$4.853 |
|
| BIO | AVITA MEDICAL INC | $0.57 | $0.87 | $0.12 |
$0.85 |
|
| CSL | CSL LIMITED | $276.47 | $313.55 | $256.15 | 27.0 |
$335.125 |
| CUV | CSL LIMITED | $13.04 | $18.20 | $12.94 |
$19.083 |
|
| GSS | GENETIC SIGNATURES LIMITED | $0.70 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.31 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMU | IMMUTEP LIMITED | $0.04 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | MICROBA LIFE SCIENCES LIMITED | $0.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $1.51 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NEU | NEUREN PHARMACEUTICALS LIMITED | $12.36 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NUZ | NEUREN PHARMACEUTICALS LIMITED | $0.19 | $xx.xx | $xx.xx | xx.x | xx.xx |
| OPT | NEUREN PHARMACEUTICALS LIMITED | $0.61 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | PARADIGM BIOPHARMACEUTICALS LIMITED | $0.33 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PER | PERCHERON THERAPEUTICS LIMITED | $0.07 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PNV | POLYNOVO LIMITED | $1.98 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PYC | PYC THERAPEUTICS LIMITED | $0.19 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $22.58 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Dr Boreham’s Crucible: Aroa Biosurgery
Jul 29 2024
Tim Boreham revisits the investment case and corporate developments for Aroa Biosurgery
CSL Shares Breaking Free
Jul 23 2024
Michael Gable of Fairmont Equities observes CSL shares are breaking through a ceiling that has held for four years, suggesting major upside potential
Dr Boreham’s Crucible: SDI
Jul 19 2024
The New Criterion’s Tim Boreham shines the light on family-run dental products manufacturer SDI (Formerly Southern Dental Industries)
‘Defensive’ Pharmaceutical Wholesalers In Focus
Jul 18 2024
New research on the Pharmaceutical Wholesaling sector identifies three stocks with long-term defensive growth within an improving government funding framework
Twists And Turns Of Telix And Australian Biotech
Jul 10 2024
In the wake of Telix Pharmaceuticals’ non-IPO on the Nasdaq, FNArena shines a light on the company’s fortunes and that of Australian biotech and cancer research generally
Dr Boreham’s Crucible: Radiopharm Theranostics
Jul 03 2024
The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising
Dr Boreham’s Crucible: Island Therapeutics
Jun 17 2024
The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports
Dr Boreham’s Crucible: Amplia Therapeutics
Jun 05 2024
Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports
Is The Long Wait For CSL About To End?
May 30 2024
The Chartist reports it looks like CSL shares might be ready to leave the past four-year pause in the past
Dr Boreham’s Crucible: Invion
May 13 2024
As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission
Latest News
| 1 |
The Market In Numbers – 23 Nov 2024Nov 23 2024 - Australia |
| 2 |
ASX Winners And Losers Of Today – 22-11-24Nov 22 2024 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 22-11-2024Nov 22 2024 - Australia |
| 4 |
Next Week At A Glance – 25-29 Nov 2024Nov 22 2024 - Weekly Reports |
| 5 |
Weekly Top Ten News Stories – 22 November 2024Nov 22 2024 - Weekly Reports |